Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KHK | P50053 | 10/20 | 0.65 |
| ▸ | HTR6 | P50406 | 6/20 | 0.54 |
| ▸ | DRD2 | P14416 | 5/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
| ▸ | DRD3 | P35462 | 6/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5097566 | 0.89 | KHK (0.54) | KHKHTR6DRD2HTR1ADRD3 | |
| SCHEMBL5097229 | 0.88 | KHK (0.66) | KHKHTR6DRD3 | |
| SCHEMBL5103783 | 0.83 | KHK (0.51) | KHKHTR6DRD2HTR1AKDM4E | |
| SCHEMBL14140342 | 0.83 | HTR6 (0.54) | KHKHTR6DRD2HTR1ADRD3 | |
| SCHEMBL5103496 | 0.83 | HTR6 (0.54) | KHKHTR6DRD2HTR1ADRD3 | |
| SCHEMBL5095214 | 0.82 | KHK (0.49) | KHKHTR6DRD2HTR1AKDM4E | |
| SCHEMBL5103473 | 0.81 | HTR6 (0.48) | KHKHTR6DRD2HTR1ADRD3 | |
| SCHEMBL5095045 | 0.80 | KHK (0.47) | KHKHTR6DRD3KDM4E | |
| SCHEMBL2550464 | 0.79 | KHK (1.00) | KHKKDM4E | |
| SCHEMBL5103448 | 0.78 | KHK (0.55) | KHKHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101641329-A | Has 5-HT 6Indoles and indazole derivatives that 6 ＇ of receptor affinity replace | MEMORY PHARM CORP US | 2010-02-03 | — | — | CN | claimed |
| US-20080200471-A1 | 6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-08-21 | — | — | US | claimed |
| US-20080200471-A1 | 6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080200471-A1 | 6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080200471-A1 | 6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-08-21 | — | — | US | disclosed |
| WO-2008101247-A2 | 6 ' SUBSTITUTED INDOLE AND INDAZOLE DERIVATIVES HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200471-A1 | 6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | HTR6, HTR1B, HTR1A | KHK 3564/4885HTR6 1/4885DRD2 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.